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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.020MCM7 is one of the pivotal DNA replication licensing factors in controlling DNA synthesis and cell entry
into S phase. Its expression and DNA copy number are some of the most predictive factors for the
growth and behavior of human malignancies. In this study, we identiﬁed that MCM7 interacts with the
receptor for activated protein kinase C 1 (RACK1), a protein kinase C (PKC) adaptor, in vivo and in vitro.
The RACK1 binding motif in MCM7 is located at the amino acid 221-248. Knocking down RACK1
signiﬁcantly reduced MCM7 chromatin association, DNA synthesis, and cell cycle entry into S phase.
Activation of PKC by 12-O-tetradecanoylphorbol-13-acetate dramatically decreased MCM7 DNA repli-
cation licensing and induced cell growth arrest. Activation of PKC induced redistribution of RACK1 from
nucleus to cytoplasm and decreased RACK1-chromatin association. The MCM7 mutant that does not bind
RACK1 has no DNA replication licensing or oncogenic transformation activity. As a result, this study
demonstrates a novel signaling mechanism that critically controls DNA synthesis and cell cycle
progression. (Am J Pathol 2013, 182: 796e805; http://dx.doi.org/10.1016/j.ajpath.2012.11.020)Supported by National Cancer Institute grants RO1 CA098249 and R56
CA098249 (J.H.L.) and the American Cancer Society (RSG-08-137-01-
CNE to Y.P.Y.).Miniature chromosome maintenance (MCM) proteins were
initially identiﬁed from autonomously replicating sequence
in Saccharomyces cerevisiae. Mutations of some of these
proteins, such as MCM7 or MCM3 result in loss of the large
chunk of yeast chromosomes in yeast. MCM7 cDNA encodes
a 543-amino acid protein and is ubiquitously expressed in all
tissues. A large body of studies indicate that MCM7 is a crit-
ical component of DNA replication licensing complex in
the yeast and xenopus.1e4 Some studies suggest that MCM4,
MCM6, and MCM7 complex contains DNA helicase acti-
vity.5,6 DNA replication licensing complex is multimeric and
phase speciﬁc. In yeast, DNA replication licensing proteins,
such as MCM2-7 and several replication origin binding
proteins, such as Cdc6, germinin, and Cdt1, form DNA
replication licensing complex in G1 phase to enable DNA
replication and to promote cell cycle entry into S phase. Initial
implication of MCM7 involvement in human malignancies
came from positive immunostaining of MCM7 in several
human malignancies, including endometrial carcinoma,7
melanoma,8 esophageal adenocarcinoma,9 colorectal adeno-
carcinoma,10 oral squamous cell carcinoma,11 glioblas-
toma,12 and thyroid cancer.13 The ﬁrst study addressing the
oncogenic role of MCM7 in prostate cancer came from
genome analysis of prostate cancer by performing a genomestigative Pathology.
.wide copy number analysis using biotin-labeled genome
DNA on Affymetrix U95av2 chip.14 The DNA copy number
of MCM7 was found to increase severalfold accompanied
with a concomitant increase of MCM7 mRNA level. Subse-
quent validation analyses suggest that either copy number
and/or protein level increase of MCM7 are associated with
prostate cancer relapse and metastasis. Ampliﬁcation of
MCM7 was also found in esophageal carcinoma.9 The
magnitude of MCM7 ampliﬁcation correlates with the
expression of MCM7, tumor grades, and the aggressiveness
of esophageal cancer.9 It is presumed that ampliﬁcation of
MCM7 is the driving force of MCM7 overexpression in
primary humanmalignancies.MCM7 is probably the primary
target of Rb, the tumor suppressor that controls cell entry into
S phase.15 There is growing evidence that other signaling
pathways also regulate MCM7 activity.
Receptor for activated protein kinase C 1 (RACK1), was
initially identiﬁed as an adaptor of several protein kinase C
(PKC) isoforms.16 The binding of RACK1 and PKC anchor
PKC to its substrate to initiate secondmessenger signaling. It is
MCM7 Interacts with RACK1suggested, according to recent studies that RACK1 interacts
with a variety of other signaling molecules, including ras-
GTPase activating protein,17 dynamin-1,18 src,19 integrins,20
PTPm,21 phosphodiesterase,22 hypoxia induced factor-1,23
and so forth, that play an important role in several physio-
logical processes, including, growth, hypoxia response,
migration, adhesion, and cell differentiation. RACK1 only
binds PKC activated by diacylglycerol or phorbol ester, but
not quiescent PKC. In this study, we showed that RACK1
binds with MCM7 N-terminus. The MCM7/RACK1 interac-
tion appears essential for DNA replication activity of MCM7.
Materials and Methods
Plasmid Construction
For construction of pCDNA4-TO-TO-MCM7, primers (50-
TGCATAAGCTTACGTTTCGCGCCAATTTCGGTT-30/50-
TAGTTCTAGAGACAAAAGTGATCCGTGTCCGGGA-30)GST-MCM72a (aa59-248)
GST-MCM73a (aa98-248)
GST-MCM74a (aa125-248)
GST-MCM75a (aa165-248)
GST-MCM76a (aa221-248
GST-MCM7n (aa2-248)
GST-MCM7n6b (aa2-209)
GST-MCM7n5b (aa2-165)
GST-MCM7n4b (aa2-125)
GST-MCM7n3b (aa2-98)
GST-MCM7n2b (aa2-59)
GST    MCM7
GST-MCM7c (aa501-719)
GST-MCM7m (aa242-427)
Figure 1 N-terminus of MCM7 binds with RACK1. A: Constructs of full length (
C-terminus (pBD-MCM7c) of MCM7 with bait domain (BD) in yeast two-hybrid analys
MCM7c with pAD-RACK1 on SD agar plate with high stringent nutrient selection (SD
is the positive control, whereas co-transfection of pBD-LamC and pAD-T-antigen is
RACK1 (lanes 10 to 18) using antibodies speciﬁc for RACK1 or MCM7 to immunopr
(right panels). The immunoprecipitates were blotted with the indicated antibodi
RACK1 bound by ﬂuorescein isothiocyanate-conjugated secondary antibody for mo
secondary antibody for rabbit. D: Mapping binding motif of RACK1 on MCM7. Left:
Right: Binding assays on GST or GST-MCM7 deletion mutants with RACK1 from PC3
blotted with anti-RACK1 antibodies. Top blots: Immunoblots with antibodies spec
The American Journal of Pathology - ajp.amjpathol.orgcorresponding to the sequence encompassing the full length
MCM7 were used in a PCR, using template of PCR-MCM7
vector. The PCR product was restricted with HindIII and
XbaI, and ligated into a similarly restricted pCDNA4-TO
vector. To construct deletion mutant of MCM7, mutagenesis
PCR was performed to generate upstream MCM7 fragment
using primers 50-TGCATAAGCTTACGTTTCGCGCCAA-
TTTCGGTT-30/50-CCAGCACCGTGATACTACGAGGGA-
TCATGAAAGTGGGAGACT-30 and downstream MCM7
fragment using primers 50-GATATGCCGATCCAGTCTCC-
CACTTTCATGATCCCTCGTAGTATCAC-30/50-TAGTTC-
TAGAGACAAAAGTGATCCGTGTCCGGGA-30. These
PCR products were combined and re-amplifed in PCR using
primers 50-TGCATAAGCTTACGTTTCGCGCCAATTTC-
GGTT-30/50-TAGTTCTAGAGACAAAAGTGATCCGTG-
TCCGGGA-30. The PCR product was then restricted with
HindIII and XbaI, and was ligated into similarly restricted
pCDNA4-TO vector to produce 28 amino acid deletion
(aa221-248). For construction of pET28a-RACK1 vector,G
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pBD-MCM7full), N-terminus (pBD-MCM7n), mid segment (pBD-MCM7m), and
is. Co-transformants of pBD-MCM7full or pBD-MCM7n, or pBD-MCM7m or pBD-
-leu-Trp-His-Ade) are shown. Co-transfection of pBD-p53 and pAD-T-antigen
the negative control. B: Co-immunoprecipitation of MCM7 (lanes 1 to 9) or
ecipitate from RWPE1 (left panels), PC3 (middle panels), and DU145 cells
es. C: Immunoﬂuorescence staining of RWPE-1 cells with antibody against
use and antibody speciﬁcally against MCM7 recognized by TRITC conjugated
Constructs of series of MCM7 deletion mutants with GST expression vectors.
cells (lanes 1 to 3) or HisTag-RACK1 (lanes 4 to 16). The bound RACK1 was
iﬁc for RACK1. Bottom blots: Coomassie staining of proteins.
797
Zhang et ala mutagenic primer set 50-AACTGCTAGCATGACTGAG-
CAGATGACCCT-30 and 50-AACTGCGGCCGCTCTAG-
CGTGTGCCAATGGTCA-30) was designed to create two
restriction sites (NheI and NotI). A PCR was performed on
pCMV-RACK1. The PCR product was restricted with NheI
andNotI, and ligated into a similarly restricted pET28a vector
to generate a Histag-RACK1 (aa2-317). To construct pCMV-
RACK1, PCR product on RACK1 cDNA using primers
50-CAGTGCCGGATCCCTCGTCGCTGCAGCGACACAC-
30/50-TTATTTGGGTACCCTCTGCCATAAACTTCTAGC-
GTGTG-30 was digested with BamH1 andKpnI. The digested
product was ligated into similarly digested pCMVscript.
Construction of Inducible MCM7 and DMCM7
Expression in PC-3 Cell Line
The plasmid pCDNA4-TO-MCM7 or the pCDNA4-TO-
DMCM7 was then co-transfected into PC3 cells with
pcDNA6. Transfected cells were selected with 500 mg/mL
Blasticidin and 1 mg/mL Zeocin (Invitrogen, Carlsbad, CA).
Clones were expanded and tested for inducible MCM7
expression by exposure to 5 mg/mL tetracycline and by
Western blot analysis with an antibody speciﬁc for MCM7Figure 2 RACK1 is essential for MCM7 chromatin association and DNA synthesi
to 8 represent immunoblot analyses of RACK1 expression in RWPE1 and PC3 cells tre
RACK1 or its vector control (pCMVscript). The chromatin (Chr) and non-chromati
antibodies speciﬁc for MCM7. Antibodies against histone 3 and glyceraldehydes
represent RWPE1 cells; lanes 17 to 24, PC3 cells. B: Knocking down of RACK1 reduc
synchronized at G0/G1 phase by serum starvation. These cells were treated with siR
cycles and DNA synthesis were then quantiﬁed 4 hours after serum stimulation. *P
PC3 cells. These cells were treated with siR1 or Scr or pCMV-RACK1 or pCMVscript
days. Colonies larger than 2 mmol/L were counted. *P < 0.01.
798and b-actin. For RACK1 knockdown assays, siRNA speciﬁc
for RACK1 (50-GAGAGGUUGUGGUGCUAGUUUCU-
CdT-30/50-AGAGAAACUAGCACCACAACCUCUCCU-30)
or for PKCBii (50-CCACAAUGACGACCUGCUUUGA-
UdTdT-30/50-AAAUCAAAGCAGGUCGUCAUUGUGGUU-
30) or scramble siRNA (50-UAAUGUAUUGGAACGCA-
UAUU-30/50-UAUGCGUUCCAAUACAUUA-30) was trans-
fected into cultured cells using lipofectamine 2000 (Invi-
trogen). The detailed procedure followed the manufacturer’s
manual.
Yeast Two-Hybrid Analysis
The yeast-competent cell preparation was previously
described.24 One hundred microliters of freshly prepared
competent AH109 cells were mixed with 0.25 to 0.50 mg
plasmid DNA plus 0.5 mg DNA from prostate yeast two-
hybrid cDNA library constructed in pACT2 in 0.5 mL of
polyethylene glycol/LiAc, incubated at 30C for 30
minutes. After this initial incubation with plasmid DNA,
the cell solution was combined with 20 mL of DMSO and
subjected to incubation for 15 minutes at 42C. The cells
were pelleted, resuspended in 1 mL YPD medium, ands. A: Knocking down of RACK1 reduced MCM7 chromatin association. Lanes 1
ated with siRNA speciﬁc for RACK1 (siR1) or scramble control (Scr) or pCMV-
n (Non-Chr) fractions of these cells were puriﬁed and immunoblotted with
-3-phosphate dehydrogenase were used as purity controls. Lanes 9 to 16
ed cell entry to S phase. RWPE1 (left panel) or PC3 (right panel) cells were
1 or Scr or pCMV-RACK1 or pCMVscript as of (A), and labeled with BrDU. Cell
< 0.01. C: Knocking down of RACK1 reduced colony formation of RWPE1 and
as in A. The cells were grown in medium supplemented with 10% FBS for 7
ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Helicase activity of MCM7 is enhanced by RACK1. A: Immu-
noblot analysis of MCM7 (WT), DMCM7D221-248 (DM7), RACK1, and b-actin
from pcDNA4-TO-MCM7/pCDNA6 (lanes 1 to 4) or pcDNA4-TOeDMCM7D221-248/
pCDNA6 transformed (lanes 5 and 6) PC3 cells. These cells were transfected
with siRNA speciﬁc for RACK1 (siR1) or scramble control (Scr) as indicated.
B: Helicase activities of MCM7 immunocomplex. MCM7 immunocomplex was
immunoprecipitated with antibodies speciﬁc for FLAG tag. Helicase assays were
performed using a Cy5-labeled DNA duplex template and biotin-labeled oligo
capture probe.
MCM7 Interacts with RACK1shaken at 30C for 40 minutes. The transformed cells were
then pelleted, resuspended in 0.5 mL 0.9% NaCl, and
plated onto the appropriate SD agar plate. The trans-
formants were ﬁrst plated on low and medium stringency
plates of SD-Leu/-Trp and SD-Leu/-Trp/-His, respectively.
The grown colonies were subjected to the b-galactosidase
assay, as previously described,24 and were allowed to
grow further in the high stringency plate (SD-Ade/-His/-
Leu/-Trp).
Immunoprecipitation
Protein extracts of PC3 cells or RWPE1 cells were
incubated with MCM7 (mouse monoclonal, 1:400) or
RACK1 (1:500, goat polyclonal) antibodies for 16 hours,
then with protein G Sepharose for 3 hours. The complex
was washed ﬁve times with radioimmunoprecipitation
assay buffer, and the bound proteins were eluted with
SDS-PAGE sample buffer. The bound RACK1 or MCM7
was electrophoresed in 10% SDS-PAGE and immuno-
blotted with anti-RACK1 antibodies or MCM7 antibodies
(1:2000).
GST Fusion Proteins Pull Down to Examine RACK1/
MCM7 Binding
The Escherichia coli cells harboring phospho glutathione
S-transferase (pGST)-MCM7 mutants or pGST were grown
in 100 mL of Luria-Bertani medium supplemented with 100
mg/mL ampicillin overnight and induced by a ﬁnal concen-
tration of 1 mmol/L isopropyl-L-thio-B-D-galactopyranoside
for 3 hours. The cells were then pelleted, resuspended in 1
PBS, and sonicated for 2 minutes. The proteins were solu-
bilized in 1% triton X-100. The supernatant was collected
after centrifugation at 15,000 g for 5 minutes. The GST,
GST-MCM7c, GST-MCM7m, GST-MCM7n, and other
MCM7 mutant fusion proteins were puriﬁed through a
Glutathione-Sepharose 4B column (Amersham Bioscience,
Piscataway, NJ). The PC3 protein extracts were pre-cleared
with the column for 15 minutes at 4C. The ﬂow-through
was collected after spinning at 3000 g for 1 minute. The
pre-cleared cell lysates were then incubated with GST fusion
protein-packed glutathione-Sepharose 4B at 4C for 2 hours.
The column was spun at 3000 g at room temperature for 1
minute and further washed twice with PBS. The proteins
were eluted from the column with 40 mL of SDS-PAGE gel
sample loading dye. SDS-PAGE and Western blot analyses
were subsequently conducted.
BrdU Labeling Analysis
To perform bromodeoxyuridine (BrdU) labeling analysis,
10 mL of BrdU solution (1 mmol/L BrdU in 1 PBS) was
added to 1 mL of tissue culture media. The treated cells were
then incubated for 3 hours at 37C. Cells were then resus-
pended with 100 mL of BD Cytoﬁx/Cytoperm Buffer perThe American Journal of Pathology - ajp.amjpathol.orgsample (BD Pharmagen, San Jose, CA) and incubated for 30
minutes at room temperature. The cells were then pelleted
and washed with 1 ml of 1 BD Perm/Wash Buffer. The
cells were then incubated with Cytoperm Plus Buffer for 10
minutes on ice. The permeation procedure was repeated
twice. The cells were resuspended with 100 mL of diluted
DNaseI (diluted to 300 mg/mL in Dulbecco’s phosphate-
buffered saline) per tube, (ie, 30 mg of DNaseI to each tube),
and were incubated for 1 hour at 37C. The cells were
washed with 1 BD Perm/Wash Buffer and incubated with
50 mL of BD Perm/Wash Buffer containing diluted ﬂuores-
cent anti-BrdU antibody (1:50) and propidium iodide for 20
minutes at room temperature. The incubation was washed
with 1 mL of 1 BD Perm/Wash Buffer. The immune-
reactivity of BrdU was assessed in LSC-II ﬂowcytometer.Immunoﬂuorescence Staining
PC3 or RWPE1 cells were cultured on chamber slides for
24 hours. The slides were washed with PBS twice. The cells
were ﬁxed with 4% paraformaldehyde for 1 hour at room799
Zhang et altemperature as previously described.25,26 After washing the
slides with PBS twice, the cells were blocked with 5% bovine
serum albumin with 0.1% Triton X-100. The cells were then
incubated with mouse monoclonal antibody against RACK1
(1:100, Santa Cruz Biotechnology, Santa Cruz, CA) ormouse
monoclonal antibody against RACK1 and rabbit antisera
against MCM7 (1:100, Santa Cruz Biotechnology) at room
temperature for 1 hour. The slides were then washed with
PBS twice. Secondary antibodies from donkey against mouse
(ﬂuorescein isothiocyanate conjugated, 1:200) or goat against
rabbit (tetramethylrhodamine-isothiocyanatee conjugated,
1:200) were added and incubated at room temperature for 1
hour. The slides were then washed with PBS twice before
addition of 4a6-diamidino-2-phenylindole. After additional
washeswith PBS, slidesweremountedwith immunomounting
buffer. Immunoﬂuorescence staining was examined under
confocal microscope.
Chromatin Association Assay
Cells were cultured to 75% conﬂuence, synchronized in
serum-free medium for 24 hours, and then treated with
tetracycline for 24 or 48 hours. These cells were washed
with PBS and trypsinized. These cells were resuspended in
1 mL of Buffer A [110 mmol/L KC2H3O2, 15 mmol/L
NaC2H3O2, 2 mmol/L MgC2H3O2, 0.5 mmol/L EGTA, andFigure 4 Activation of PKC inhibits MCM7 chromatin association. RWPE1 (lan
(lanes 5 and 6) or pCMV-DMCM7-FLAG (lanes 7 and 8) were treated with 1 mg/mL o
chromatin (non-Chr) fractions were puriﬁed and immunoblotted with antibodies s
glyceraldehydes-3-phosphate dehydrogenase were used as purity controls. Immu
Lanes 9 to 12: RWPE1 cells treated with or without TPA. Lanes 13 to 16: PC3 cells t
treated with or without TPA. Lanes 21 to 24: PC3 cells transfected with pCMV-DM
80020 mmol/L HEPES (pH 7.3)]. The cell suspension was
treated to the ﬁnal concentration of 2 mmol/L DTT and 50
mg/mL digitonin. The cells were incubated at 4C for 10
minutes in a rotator. Nuclei were pelleted by centrifugation
at 1500 g for 10 minutes. They were resuspended in
hypotonic buffer [Buffer B: 1 mmol/L HEPES (pH 7.5),
0.5 mmol/L EDTA supplemented with 0.5% NP40]. The
nuclear suspensions were then incubated at 4C for 15
minutes in a rotator and laid on top of a 10-mL sucrose
cushion [100 mmol/L sucrose and 0.5 mmol/L Tris-HCl (pH
8.5)] and centrifuged at 3500 g for 15 minutes at 4C. The
chromatin pellets were suspended in 0.25 mmol/L EDTA
(pH 8.0) and sonicated for 10 seconds twice for each
sample. The chromatin suspensions were centrifuged twice
at high speed for 10 minutes at 4C and the supernatants
were retained.
Colony Formation Assay
Colony formation assay was performed similarly, as previ-
ously described.27 Five thousand or 10,000 cells were
cultured in 60-mm dishes. Triplicate experiments were
performed for each cell clones. Medium containing 10%
fetal bovine serum (Invitrogen) was changed every 4 days.
On day 7, the plates were stained with 1% crystal violet and
the colonies with a diameter of >2 mm were counted.es 1 and 2) or PC3 (lanes 3 and 4) or PC3 cells transfected with pCMVscript
f TPA for 24 hours. These cells were harvested. The chromatin (Chr) and non-
peciﬁc for FLAG, MCM7, MCM6, and Cdt1. Antibodies against histone 3 and
noblots using antibodies speciﬁc for b-actin were used for normalization.
reated with or without TPA. Lanes 17 to 20: PC3 transfected with pCMVscript
CM7-FLAG treated with or without TPA.
ajp.amjpathol.org - The American Journal of Pathology
MCM7 Interacts with RACK1Helicase Assay
MCM7 immunoprecipitates were incubated with a PCR
product of a pUC19 template generated with primers 50-
CAAGTTGGGAAGACAACCTG-30/50-Cy5-CCAATATG-
GTGAAACCCCGT-30 using the following condition: 20
mmol/L Tris-HCl, pH 7.4, 50 mmol/L NaCl, 3 mmol/L
MgCl2, 2 mmol/L ATP, 20% glycerol, 0.1% bovine se-
rum albumin, and capture probes (Biotin-50-CAAGTTGG-
GAAGACAACCTGTAGGGCCTGCGGGGT-30) for 30
minutes at room temperature. The reaction was stopped by
170 mmol/L EDTA, pH 8.0. The probes were then captured
with streptavidin-agarose beads, and washed with Tris-
Tween-20 buffer three times. Cy5 intensity was then
quantiﬁed with Affymetrix 426 scanner. Triplicate experi-
ments were performed for each assay. Assays with agarose
beads without streptavidin were used as background
controls. WT MCM7 immune complexes from cells not
treated with siRNA were used as positive controls.Results
To investigate signaling molecules that interact and regulate
MCM7 activity, we performed a yeast two-hybrid screening
analysis on a prostate cDNA library using MCM7 full
length protein fused with the binding domain of GAL4
gene. Using pBD-MCM7, we have identiﬁed 36 positive
colonies after three rounds of metabolic screening of
a prostate yeast two-hybrid cDNA library. These colonies
were subsequently isolated. After several restriction enzyme
digestions, several redundant clones were eliminated. EightThe American Journal of Pathology - ajp.amjpathol.orgunique clones were identiﬁed and sequenced. One of these
clones contains a cDNA encoding RACK1.
To validate the yeast two-hybrid screening results,
pAD-RACK1 and pBD-MCM7 were co-transfected into
Yeast AH109 cells, grown in high stringency medium,
and tested for a-galactosidase activity. Both pBD-MCM7
(full length) and pBD-MCM7n (N-terminus) showed posi-
tive galactosidase activity, whereas the C-terminus or mid-
segment of MCM7 was negative, suggesting that the
RACK1 binding activity is mediated by a region located in
the N-terminus of MCM7 (Figure 1A). Among prostate cell
lines, RACK1 is abundantly expressed in RWPE-1 cells
(immortalized prostate epithelial cells), PC3, and DU145
cells (prostate cancer cells). To verify the interaction, an
in vivo MCM7-RACK1 binding analysis was performed in
protein extracts of RWPE1, PC3, and DU145 cells. As
shown in Figure 1B, co-immunoprecipitation of MCM7 and
RACK1 was readily apparent. To visualize whether MCM7
and RACK1 co-localize in the nucleus, double immuno-
ﬂuorescence staining using antibodies against MCM7 and
RACK1 were performed in RWPE1 cells. As demonstrated
in Figure 1C, signiﬁcant amount of RACK1 was colocalized
with MCM7 in the nuclei of RWPE1 cells. Similar coloc-
alization results were obtained with PC3 and DU145 cells
(data not shown).
To validate the interaction between MCM7 N-terminus
and RACK1 in vitro, fragments of the N-terminus (247
amino acids), mid-segment (186 amino acids), and C-
terminus (219 amino acids) of MCM7 were constructed into
pGEX-5T to create GST-MCM7n, GST-MCM7m, and
GST-MCM7c fusion proteins, respectively. In vitro MCM7/
RACK1 binding assays were performed using RACK1Figure 5 Activation of PKC inhibits cell entry
to S phase and cell growth. A: TPA inhibits cell
entry to S phase. RWPE1 (left) and PC3 (right)
cells were synchronized at G0/G1 phase by serum
starvation. These cells were treated with or
without 1 mg/mL TPA, labeled with BrdU, and
stimulated with 10% fetal bovine serum. Cell
cycles and DNA synthesis were then quantiﬁed 4
hours after serum stimulation. *P < 0.01. B:
Knocking down of RACK1 enhances TPA-mediated
cell growth arrest. RWPE1 (left) and PC3 (right)
cells were synchronized at G0/G1 phase by serum
starvation. These cells were silenced with siRACK,
or siPKCbii, or Scr control. These cells were then
treated with or without 1 mg/mL TPA, labeled with
BrDU, and stimulated with 10% fetal bovine
serum. Cell cycles and DNA synthesis were then
quantiﬁed 4 hours after serum stimulation. *P <
0.01. C: Colony formation of RWPE1 (left) and PC3
(right) cells treated with or without TPA, in the
presence of siRACK or Scr. *P < 0.05.
801
Figure 6 Activation of PKC inhibits RACK1 association with chromatin.
A: Phorbol ester treatment reduced RACK1 chromatin association. RWPE1 or
PC3 cells were treated with or without 1 mg/mL TPA for 24 hours. These cells
were harvested. The chromatin (Chr) and non-chromatin fractions (Non-Chr)
were puriﬁed and immunoblotted with antibodies speciﬁc for RACK1. Anti-
bodies against histone 3 and glyceraldehydes-3-phosphate dehydrogenase
were used as purity controls. Lanes 1 to 4: RWPE1 cells treated with or
without TPA. Lanes 5 to 8: PC3 cells treated with or without TPA. B: RACK1
redistribution from the nucleus to cytoplasm on treatment of phorbol ester.
RWPE1 or PC3 cells were treated with or without 1 mg/mL TPA for 24 hours.
Immunoﬂuorescence staining of these cells using antibodies speciﬁc for
RACK1 was performed. Representative images were shown.
Figure 7 Binding with RACK1 is essential for MCM7 DNA replication and
transformation activity. A: Immunoblot analysis of mutant MCM7 that does
not bind RACK1 in pCDNA4-TO-DMCM7D221-248/pCDNA6 transformed PC3
cells (lanes 7 and 8, DM2; lanes 5 and 6, DM6) and MCM7 wild-type
controls (lanes 1 and 2, M2; lanes 3 and 4, M4). These cells were
induced to express mutant or wild-type MCM7 with 5 mg/mL tetracycline,
and immunoblotted with antibody speciﬁc for FLAG-tag. Immunoblots with
antibodies speciﬁc for b-actin were used for normalization. B: Cell cycle
analysis of duplicate experiments from A. *P < 0.05. C: Colony formation
analysis of mutant MCM7 (DM2 and DM6) or its wild-type counterpart (M2
and M4) from A. *P < 0.05.
Zhang et alextracted from PC3 cell line and these fusion MCM7
proteins. The results of the binding assays indicate that
GST-MCM7n binds with RACK1 in the cell free system
(Figure 1D). To rule out potential bridging proteins between
RACK1 and MCM7 interaction, RACK1 cDNA was ligated
into pET-28 vector to create a HisTag-RACK1 fusion
protein. The binding analysis with the recombinant HisTag-
RACK1 and GST-MCM7 N-terminus (2-248 amino acids)
shows that the RACK1 binds with MCM7 N-terminus
directly (Figure 1D). These results indicate that the inter-
action between MCM7 and RACK1 is direct and does not
require bridge protein in their interaction. A series of dele-
tion mutants of GST-MCM7n were constructed to identify
the motifs that are required to interact with RACK1. A
stretch of 28 amino acid sequence located in 221-248 of
MCM7 was found crucial for MCM7 binding with RACK1,802because the fusion proteins deleted of this sequence did not
bind with RACK1, whereas all proteins containing this
sequence bound with RACK1 (Figure 1D).
RACK1 is an adaptor of protein kinase C and several other
signaling molecules. To investigate whether interaction of
RACK1 and MCM7 has impact on the function of MCM7,
RACK1 protein expression was knocked down using siRNA
speciﬁc for RACK1 50UTR and MCM7 chromatin associa-
tion analysis was performed. As shown in Figure 2A,
knocking down of RACK1 in either RWPE1 or PC3 cells
signiﬁcantly reduced MCM7 association with chromatin. To
rule out off-target effects of siRACK1,RWPE1, and PC3 cellsajp.amjpathol.org - The American Journal of Pathology
Figure 8 Schematic diagram of interplay of PKC, RACK1, and MCM7. PKC
binding with TPA leads to activation of PKC and PKC/RACK1 binding. This
event redistributes RACK1 from nucleus to cytoplasm, inactivation of MCM7,
and disintegration of DNA replication licensing complex.
MCM7 Interacts with RACK1that were co-transfected with siRACK1 and pCMV-RACK1,
which does not contain the sequence corresponding to siR-
ACK1. The chromatin associatedMCM7was reversed on the
expression of this exogenous RACK1. On knocking down of
RACK1, there was a 20% reduction of BrdU labeling in
RWPE1 cells and a 30% drop (P< 0.001) of cells entering S
phase and concomitant 26% increase of G0/G1 phase for
RWPE1 cells (P < 0.001) (Figure 2B). For PC3 cells, the
decrease of S phase is 45% (P< 0.001) and the increase ofG0/
G1 phase is 25% (P < 0.001). Similar to chromatin associa-
tion analyses, the cell growth arrest effects were reversedwith
pCMV-RACK1. Knocking down of RACK1 also reduced
colony formation of both RWPE1 and PC3 cells by 47% (P<
0.01) and 45% (P < 0.01) (Figure 2C), respectively.
Furthermore, knocking down of RACK1 had a dramatic
negative impact on MCM7 helicase activity (Figure 3).
MutantMCM7 that does not interactwithRACK1had limited
helicase activity. These results clearly suggest that RACK1
plays an important role in inducing MCM7 DNA replication
licensing, in advancing cell cycle, and in cell growth.
To investigate the effect of protein kinase C (PKC)-
RACK1 signaling pathway on MCM7 DNA replication
licensing activity, RWPE1 and PC3 cells were treated with
1 mg/mL PKC activator, 12-O-tetradecanoylphorbol-13-
acetate (TPA). These cells were then examined for MCM7
replication licensing activity. As shown in Figure 4, activa-
tion of PKC is accompanied with signiﬁcant dissociation of
MCM7 from the chromatin fraction in both RWPE1 and PC3
cells. Interestingly, the activation of PKC not only reduced
MCM7 chromatin association but also other components of
DNA replication licensing complex, such as Cdt1 andMCM6
(Figure 4), suggesting a disintegration of DNA replication
complex on PKC activation. Mutant MCM7 that is deleted of
amino acid 221-248 and is defective of RACK1 interaction
was not responsive to TPA stimulation, and appeared to
inhibit other licensing factor for chromatin de-association
(Figure 4). Indeed, treatment of PC3 and RWPE1 cells with
TPA induced dramatic cell cycle arrest with an increase ofThe American Journal of Pathology - ajp.amjpathol.orgG0/G1 phase by more than 100% in RWPE1 cells (P <
0.001) and 56% (P< 0.001) in PC3 cells, and a decrease of S
phase by 49% (P < 0.001) in RWPE1 and 27% (PZ 0.002)
in PC3 cells (Figure 5A). Knocking down of RACK1
enhanced the TPA-induced growth arrest (G0/G1 phase)
effect by an additional 50% (P< 0.001) in RWPE1 cells and
35% (P< 0.001) in PC3 cells (Figure 5B). Knocking down of
PKCbII, the major RACK1-binding PKC family member,
resulted in signiﬁcant blunting of cell growth arrest induced
by TPA (23.7% of scramble control on S phase reduction of
RWPE1 cells, P < 0.05, and 38.5% for PC3 cells, P < 0.05)
(Figure 5B). Colony formation analyses also showed that
treatment of TPA dramatically inhibited colony formation
(Figure 5C). These results indicate that PKC-RACK1
signaling serves to inactivate RACK1/MCM7 DNA repli-
cation licensing, to block cell entry into S phase, and to inhibit
cell growth in the prostate cancer and immortalized prostate
epithelial cells.
To investigate whether RACK1 binding of MCM7 leads
to RACK1 chromatin association, chromatin association
analysis of RACK1 was analyzed. As shown in Figure 6,
a signiﬁcant amount of RACK1 was found in chromatin
fraction. On stimulation of TPA, however, dramatic disso-
ciation of RACK1 from chromatin occurred in both RWPE1
and PC3 cells. These ﬁndings are accompanied with an
increase of RACK1 in the cytoplasm after treatment of TPA
(Figure 6B). These ﬁndings suggest that PKC activation
prevents entry of RACK into the nucleus, and thus the
binding with MCM7.
To investigate whether RACK1-MCM7 interaction is
essential for chromatin association activity of MCM7,
a MCM7 mutant with 28 amino acid RACK1 interaction
motifs (amino acids 221-248) deleted, was inserted into
pCDNA4-TO to create pCDNA4-TO-DMCM7. This vector
was subsequently transfected into PC3 cells. Two clones
(DM2 and DM6) with tetracycline inducible expression
of mutant MCM7 were selected for further analyses. As
shown in Figure 7, mutant MCM7 did not generate additional
S phase entry in cell cycle analysis, even though its wild-type
counterpart signiﬁcantly increased the S phase and decreased
G0/G1 phases, supporting that RACK1 interaction is neces-
sary for MCM7 DNA replication licensing. Overall, these
results support the fact that interaction of RACK1/MCM7
plays an important role in DNA replication licensing and
activation of PKC leads to redistribution of RACK1 and
inhibition of RACK1/MCM7 mediated replication licensing.Discussion
MCM7 is one of the major components of DNA replication
licensing complex. Numerous studies suggest that MCM7 is
a pivotal point in regulating DNA replication licensing
activity by interacting with several signaling molecules,28
including retinoblastoma gene, androgen receptor, and
integrin linked kinase. The present study indicates that803
Zhang et alRACK1 interacts and activates MCM7 both in vivo and
in vitro. Several lines of evidence support that MCM7 binds
with RACK1. First, both full length and the N-terminus of
MCM7 binds RACK1 in the yeast two-hybrid system and
cell free in vitro binding assays. The cell-free recombinant
MCM7 N-terminus and Histag-RACK1 binding suggests
that no bridge protein is involved in MCM7/RACK1
interaction. Second, both MCM7 and RACK1 are readily
co-immunoprecipitated from prostate epithelial cells and
prostate cancer cells by antibodies either against RACK1 or
MCM7, suggesting MCM7/RACK1 interaction occurring
intracellularly. Third, MCM7 and RACK1 are co-localized
in the nucleus of immortalized prostate epithelial and
prostate cancer cells. Interestingly, RACK1/MCM7 inter-
action appears to occur only in nucleus because no coloc-
alization MCM7/RACK1 was detected in the cytoplasm of
these cells. By identifying MCM7/RACK1 interaction, this
study reveals a critical role of MCM7 in relaying signaling
from stimulation of PKC to DNA replication. PKC is
a family of kinases regulated by calcium, diacylglycerol and
phorbol ester.29 Depending on their response to calcium and
phorbol ester, PKC is generally divided into three different
classes: classical PKC that responds to both calcium and
phorbol ester; novel PKC that responds to lipid ligands
such as diacylglycerol and phorbol ester but not calcium;
atypical PKC responds to none of these stimulants.
Depending on the circumstances, PKC can be either an
oncogene or a tumor suppressor gene.30 Indeed, several
novel and classical PKC members have been shown to be
anti-proliferative in prostate epithelial cells.31,32 The
mechanism for PKC-mediated anti-proliferative activity in
prostate cancer and prostate epithelial cells has been elusive.
This study, to our best knowledge, provides the ﬁrst direct
link of PKC signaling in regulating cell proliferation by
revealing a novel signaling pathway of PKC-RACK1-
MCM7.
RACK1 has been shown to be an important adaptor for
several signaling molecules, including PKC,33 integrin,34 and
c-abl.35 RACK1 also plays an important role in several
cellular physiological processes. In contrast to previous
studies, our analysis reveals that RACK1 is a versatile
protein, located in both cytoplasm and the nucleus. A
signiﬁcant amount of RACK1 is located in the nucleus and is
associated with chromatin. Removal of RACK1 from the
chromatin complex by knocking down RACK1 protein
expression or removal of RACK1-bindingmotif fromMCM7
severely compromised the DNA replication licensing
activity, and results in stalling of entry into S phase. As
a result, RACK1 appears to play a critical role in DNA
replication licensing, far beyond an adaptor role for other
signaling molecules. It is not entirely clear what drives
RACK1 redistribution from the nucleus to cytoplasm on PKC
activation. Because quiescent PKCs do not bind RACK1, it is
possible that the binding of RACK1 by activated PKC alters
the structural conformation and leads to shifting RACK1
from the nucleus to cytoplasm. Alternatively, competitive804binding of activated PKC andMCM7 to RACK1 is a possible
mechanism. Based on these ﬁndings, we argue that one of the
natural physiological roles of RACK1 is a replication co-
factor in DNA replication machinery (Figure 8). The DNA
replication licensing factors may not be limited to factors of
a core complex, such as Cdt1, geminin, MCM components,
but also to factors dictating the function of this complex, such
as AR, Rb, and RACK1. Interestingly, the AR and RACK1
bindingmotif inMCM7 overlap.While RACK1 bindingwith
MCM7 appears to enhance the DNA replication licensing, the
binding of AR with MCM7 appears inhibitory (with a high
dosage of AR ligand).36 AR recruits MCM7 for its tran-
scription activity.36 This analysis suggests that AR and
RACK1 cross talk through MCM7 to balance cellular DNA
synthesis and RNA transcription; an AR-bound MCM7
primarily functions as a co-transcription factor, whereas
a RACK1-bound MCM7 functions as a DNA helicase.
MCM7 overexpression and ampliﬁcation were found in
multiple malignancies. Ampliﬁcation and a high level of
expression of MCM7 were found to associate poor clinical
outcomes, probably due to misﬁring of MCM7 that results in
hyperploidy and other genome abnormalities.9,14 Intron 13
of MCM7 genome contains a cluster of miRNA that was
found to down-regulate several important tumor suppressors,
including p21, BIM, and pTEN.9,37e40 This makes MCM7
gene cluster an intriguing oncogenic complex. There is
a growing body of literature suggesting that MCM7 plays
a gate-keeping role in communicating DNA replication
licensing with both anti-proliferative and pro-proliferative
signaling pathways. The unique pivotal role of MCM7
opens the door for future therapeutic intervention on human
malignancies. Indeed, our previous study showed that treat-
ment using shRNA speciﬁc for MCM7 dramatically reduced
tumor size, metastasis, and mortality in xenografted PC3,
DU145 tumors in severe combined immunodeﬁciency
mice.41 This analysis implies that targeted molecule up-
stream of MCM7 is a possible approach to control the acti-
vity of DNA replication licensing, and thus proliferation,
possibly migration, and metastasis of human malignancies.References
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